In vitro, fedratinib significantly enhanced the cytotoxicity of erlotinib in erlotinib-resistant non-small cell lung carcinoma (NSCLC) cells with epidermal growth factor receptor mutations, and inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo [89]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.